Schott Pharma refines its long-term growth strategy, shares in the SDAX health segment

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-22, 17:10.

Schott Pharma (DE000A3ENQ51) focuses on long-term growth with specialized drug containment and delivery solutions for injectable medicines. The shares trade in the SDAX on Xetra among German medical equipment names, tying the stock to the broader European health-care small-cap universe.

How Schott Pharma positions for growth

Schott Pharma centers its business model on primary packaging and delivery systems for injectable drugs, including vials, prefillable syringes and cartridges for biopharmaceuticals and vaccines. A key pillar is customized solutions for complex biologics that require high-quality glass and polymer systems to maintain drug stability.

The company emphasizes collaborations with large pharmaceutical customers to co-develop containment and delivery designs that fit specific molecules and administration routes, such as prefilled syringes for self-administration therapies. This positioning is intended to align Schott Pharma with structural trends toward injectable biologics and chronic disease treatments according to company information on its investor pages.Schott Pharma investor information

Role in the SDAX health segment

Schott Pharma shares are part of the SDAX, which includes smaller German companies across sectors and provides an institutional reference index for domestic investors. Within this universe, Schott Pharma sits in the medical equipment category, alongside other health-related manufacturers.

The SDAX is often used by market participants as a benchmark for German small and mid-cap strategies, and Schott Pharma thereby competes for capital with industrial and technology peers as well as health-care names. Sector and index membership can influence fund flows, particularly for passive and factor-based strategies that include SDAX constituents, as reflected in index provider and market commentary from German small-cap reports.Finanzen100 profile on Schott Pharma

What the company sells

Schott Pharma generates revenue with primary packaging and delivery systems for injectable drugs, including glass vials, polymer vials, prefillable syringes and cartridges designed for vaccines, biologics and other parenteral medications. Its portfolio targets pharmaceutical customers seeking reliable drug containment, patient-friendly delivery and support for complex formulations.

Where the stock trades today

The Schott Pharma shares (DE000A3ENQ51) most actively trade on Xetra in euros as part of the SDAX medical equipment segment. As of the latest available intraday quotation referenced on German price services, the stock changes hands on Xetra in the low double-digit euro range.

This article is for informational purposes only and does not constitute investment advice, investment recommendation or an offer or solicitation to buy or sell any financial instrument. Investors should conduct their own research and consider seeking independent financial advice before making investment decisions.